Literature DB >> 2246037

Insulin resistance and blood pressure in young black men.

B Falkner1, S Hulman, J Tannenbaum, H Kushner.   

Abstract

Insulin resistance, independent of obesity or non-insulin-dependent diabetes mellitus, has been demonstrated to be associated with high blood pressure. To determine if insulin resistance could be an antecedent to hypertension in a high-risk population, we studied normotensive (112 +/- 12/70 +/- 10 mm Hg) and borderline hypertensive (135 +/- 8/85 +/- 5 mm Hg) lean young black men (22-26 years old) with the euglycemic hyperinsulinemic clamp technique. All subjects had clinically normal oral glucose tolerance. Body mass index and percent adipose mass were the same in both groups. Fasting plasma insulin concentration was significantly higher in the borderline hypertensive group (p less than 0.01). Insulin-directed exogenous glucose metabolism at the same degree of steady-state hyperinsulinemia was significantly lower in the borderline hypertensive group (5.98 +/- 2.22 versus 8.22 +/- 1.96 mg/kg/min; p less than 0.01). For the total population, a significant inverse correlation existed between the glucose infusion rate and systolic blood pressure (p less than 0.01). These data indicate that there is a relation between insulin-mediated glucose uptake and blood pressure. Furthermore, in this high-risk population insulin resistance may precede the onset of established essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2246037     DOI: 10.1161/01.hyp.16.6.706

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Gender differences in insulin-induced free fatty acid suppression: studies in an African American population.

Authors:  A E Sumner; H Kushner; C A Lakota; B Falkner; J B Marsh
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

2.  Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance.

Authors: 
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

3.  High risk blood pressure and obesity increase the risk for left ventricular hypertrophy in African-American adolescents.

Authors:  Bonita Falkner; Stephanie DeLoach; Scott W Keith; Samuel S Gidding
Journal:  J Pediatr       Date:  2012-07-19       Impact factor: 4.406

Review 4.  Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease.

Authors:  G M Reaven; A Laws
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study.

Authors:  E J Feskens; J Tuomilehto; J H Stengård; J Pekkanen; A Nissinen; D Kromhout
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

6.  Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells.

Authors:  P R Standley; F Zhang; J L Ram; M B Zemel; J R Sowers
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance.

Authors:  W Y Fujimoto; R W Bergstrom; D L Leonetti; L L Newell-Morris; W P Shuman; P W Wahl
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

Review 8.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

9.  Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension.

Authors:  C L Gaboury; D C Simonson; E W Seely; N K Hollenberg; G H Williams
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 10.  Race and hypertension. What is clinically relevant?

Authors:  D R Rutledge
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.